Design of Alphavirus Virus-Like Particles Presenting Circumsporozoite Junctional Epitopes That Elicit Protection against Malaria
The most advanced malaria vaccine, RTS,S, includes the central repeat and C-terminal domains of the <i>Plasmodium falciparum</i> circumsporozoite protein (PfCSP). We have recently isolated human antibodies that target the junctional region between the N-terminal and repeat domains that a...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/9/3/272 |
_version_ | 1797540891710193664 |
---|---|
author | Joseph R. Francica Wei Shi Gwo-Yu Chuang Steven J. Chen Lais Da Silva Pereira S. Katie Farney Barbara J. Flynn Li Ou Tyler Stephens Yaroslav Tsybovsky Lawrence T. Wang Alexander Anderson Zoltan Beck Marlon Dillon Azza H. Idris Nicholas Hurlburt Tracy Liu Baoshan Zhang Carl R. Alving Gary R. Matyas Marie Pancera John R. Mascola Peter D. Kwong Robert A. Seder |
author_facet | Joseph R. Francica Wei Shi Gwo-Yu Chuang Steven J. Chen Lais Da Silva Pereira S. Katie Farney Barbara J. Flynn Li Ou Tyler Stephens Yaroslav Tsybovsky Lawrence T. Wang Alexander Anderson Zoltan Beck Marlon Dillon Azza H. Idris Nicholas Hurlburt Tracy Liu Baoshan Zhang Carl R. Alving Gary R. Matyas Marie Pancera John R. Mascola Peter D. Kwong Robert A. Seder |
author_sort | Joseph R. Francica |
collection | DOAJ |
description | The most advanced malaria vaccine, RTS,S, includes the central repeat and C-terminal domains of the <i>Plasmodium falciparum</i> circumsporozoite protein (PfCSP). We have recently isolated human antibodies that target the junctional region between the N-terminal and repeat domains that are not included in RTS,S. Due to the fact that these antibodies protect against malaria challenge in mice, their epitopes could be effective vaccine targets. Here, we developed immunogens displaying PfCSP junctional epitopes by genetic fusion to either the N-terminus or B domain loop of the E2 protein from chikungunya (CHIK) alphavirus and produced CHIK virus-like particles (CHIK-VLPs). The structural integrity of these junctional-epitope–CHIK-VLP immunogens was confirmed by negative-stain electron microscopy. Immunization of these CHIK-VLP immunogens reduced parasite liver load by up to 95% in a mouse model of malaria infection and elicited better protection than when displayed on keyhole limpet hemocyanin, a commonly used immunogenic carrier. Protection correlated with PfCSP serum titer. Of note, different junctional sequences elicited qualitatively different reactivities to overlapping PfCSP peptides. Overall, these results show that the junctional epitopes of PfCSP can induce protective responses when displayed on CHIK-VLP immunogens and provide a basis for the development of a next generation malaria vaccine to expand the breadth of anti-PfCSP immunity. |
first_indexed | 2024-03-10T13:07:30Z |
format | Article |
id | doaj.art-277cfc8acf7447ca984b6d9fdb635f46 |
institution | Directory Open Access Journal |
issn | 2076-393X |
language | English |
last_indexed | 2024-03-10T13:07:30Z |
publishDate | 2021-03-01 |
publisher | MDPI AG |
record_format | Article |
series | Vaccines |
spelling | doaj.art-277cfc8acf7447ca984b6d9fdb635f462023-11-21T10:59:23ZengMDPI AGVaccines2076-393X2021-03-019327210.3390/vaccines9030272Design of Alphavirus Virus-Like Particles Presenting Circumsporozoite Junctional Epitopes That Elicit Protection against MalariaJoseph R. Francica0Wei Shi1Gwo-Yu Chuang2Steven J. Chen3Lais Da Silva Pereira4S. Katie Farney5Barbara J. Flynn6Li Ou7Tyler Stephens8Yaroslav Tsybovsky9Lawrence T. Wang10Alexander Anderson11Zoltan Beck12Marlon Dillon13Azza H. Idris14Nicholas Hurlburt15Tracy Liu16Baoshan Zhang17Carl R. Alving18Gary R. Matyas19Marie Pancera20John R. Mascola21Peter D. Kwong22Robert A. Seder23Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USAVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USAVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USAVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USAVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USAVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USAVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USAVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USAElectron Microscopy Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, MD 21701, USAElectron Microscopy Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, MD 21701, USAVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USALaboratory of Adjuvant & Antigen Research, US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USALaboratory of Adjuvant & Antigen Research, US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USAVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USAVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USAVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USAVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USAVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USALaboratory of Adjuvant & Antigen Research, US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USALaboratory of Adjuvant & Antigen Research, US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USAVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USAVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USAVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USAVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USAThe most advanced malaria vaccine, RTS,S, includes the central repeat and C-terminal domains of the <i>Plasmodium falciparum</i> circumsporozoite protein (PfCSP). We have recently isolated human antibodies that target the junctional region between the N-terminal and repeat domains that are not included in RTS,S. Due to the fact that these antibodies protect against malaria challenge in mice, their epitopes could be effective vaccine targets. Here, we developed immunogens displaying PfCSP junctional epitopes by genetic fusion to either the N-terminus or B domain loop of the E2 protein from chikungunya (CHIK) alphavirus and produced CHIK virus-like particles (CHIK-VLPs). The structural integrity of these junctional-epitope–CHIK-VLP immunogens was confirmed by negative-stain electron microscopy. Immunization of these CHIK-VLP immunogens reduced parasite liver load by up to 95% in a mouse model of malaria infection and elicited better protection than when displayed on keyhole limpet hemocyanin, a commonly used immunogenic carrier. Protection correlated with PfCSP serum titer. Of note, different junctional sequences elicited qualitatively different reactivities to overlapping PfCSP peptides. Overall, these results show that the junctional epitopes of PfCSP can induce protective responses when displayed on CHIK-VLP immunogens and provide a basis for the development of a next generation malaria vaccine to expand the breadth of anti-PfCSP immunity.https://www.mdpi.com/2076-393X/9/3/272junctional epitopemalarianeutralizing antibodiesparasite<i>Plasmodium falciparum</i>vaccines |
spellingShingle | Joseph R. Francica Wei Shi Gwo-Yu Chuang Steven J. Chen Lais Da Silva Pereira S. Katie Farney Barbara J. Flynn Li Ou Tyler Stephens Yaroslav Tsybovsky Lawrence T. Wang Alexander Anderson Zoltan Beck Marlon Dillon Azza H. Idris Nicholas Hurlburt Tracy Liu Baoshan Zhang Carl R. Alving Gary R. Matyas Marie Pancera John R. Mascola Peter D. Kwong Robert A. Seder Design of Alphavirus Virus-Like Particles Presenting Circumsporozoite Junctional Epitopes That Elicit Protection against Malaria Vaccines junctional epitope malaria neutralizing antibodies parasite <i>Plasmodium falciparum</i> vaccines |
title | Design of Alphavirus Virus-Like Particles Presenting Circumsporozoite Junctional Epitopes That Elicit Protection against Malaria |
title_full | Design of Alphavirus Virus-Like Particles Presenting Circumsporozoite Junctional Epitopes That Elicit Protection against Malaria |
title_fullStr | Design of Alphavirus Virus-Like Particles Presenting Circumsporozoite Junctional Epitopes That Elicit Protection against Malaria |
title_full_unstemmed | Design of Alphavirus Virus-Like Particles Presenting Circumsporozoite Junctional Epitopes That Elicit Protection against Malaria |
title_short | Design of Alphavirus Virus-Like Particles Presenting Circumsporozoite Junctional Epitopes That Elicit Protection against Malaria |
title_sort | design of alphavirus virus like particles presenting circumsporozoite junctional epitopes that elicit protection against malaria |
topic | junctional epitope malaria neutralizing antibodies parasite <i>Plasmodium falciparum</i> vaccines |
url | https://www.mdpi.com/2076-393X/9/3/272 |
work_keys_str_mv | AT josephrfrancica designofalphavirusviruslikeparticlespresentingcircumsporozoitejunctionalepitopesthatelicitprotectionagainstmalaria AT weishi designofalphavirusviruslikeparticlespresentingcircumsporozoitejunctionalepitopesthatelicitprotectionagainstmalaria AT gwoyuchuang designofalphavirusviruslikeparticlespresentingcircumsporozoitejunctionalepitopesthatelicitprotectionagainstmalaria AT stevenjchen designofalphavirusviruslikeparticlespresentingcircumsporozoitejunctionalepitopesthatelicitprotectionagainstmalaria AT laisdasilvapereira designofalphavirusviruslikeparticlespresentingcircumsporozoitejunctionalepitopesthatelicitprotectionagainstmalaria AT skatiefarney designofalphavirusviruslikeparticlespresentingcircumsporozoitejunctionalepitopesthatelicitprotectionagainstmalaria AT barbarajflynn designofalphavirusviruslikeparticlespresentingcircumsporozoitejunctionalepitopesthatelicitprotectionagainstmalaria AT liou designofalphavirusviruslikeparticlespresentingcircumsporozoitejunctionalepitopesthatelicitprotectionagainstmalaria AT tylerstephens designofalphavirusviruslikeparticlespresentingcircumsporozoitejunctionalepitopesthatelicitprotectionagainstmalaria AT yaroslavtsybovsky designofalphavirusviruslikeparticlespresentingcircumsporozoitejunctionalepitopesthatelicitprotectionagainstmalaria AT lawrencetwang designofalphavirusviruslikeparticlespresentingcircumsporozoitejunctionalepitopesthatelicitprotectionagainstmalaria AT alexanderanderson designofalphavirusviruslikeparticlespresentingcircumsporozoitejunctionalepitopesthatelicitprotectionagainstmalaria AT zoltanbeck designofalphavirusviruslikeparticlespresentingcircumsporozoitejunctionalepitopesthatelicitprotectionagainstmalaria AT marlondillon designofalphavirusviruslikeparticlespresentingcircumsporozoitejunctionalepitopesthatelicitprotectionagainstmalaria AT azzahidris designofalphavirusviruslikeparticlespresentingcircumsporozoitejunctionalepitopesthatelicitprotectionagainstmalaria AT nicholashurlburt designofalphavirusviruslikeparticlespresentingcircumsporozoitejunctionalepitopesthatelicitprotectionagainstmalaria AT tracyliu designofalphavirusviruslikeparticlespresentingcircumsporozoitejunctionalepitopesthatelicitprotectionagainstmalaria AT baoshanzhang designofalphavirusviruslikeparticlespresentingcircumsporozoitejunctionalepitopesthatelicitprotectionagainstmalaria AT carlralving designofalphavirusviruslikeparticlespresentingcircumsporozoitejunctionalepitopesthatelicitprotectionagainstmalaria AT garyrmatyas designofalphavirusviruslikeparticlespresentingcircumsporozoitejunctionalepitopesthatelicitprotectionagainstmalaria AT mariepancera designofalphavirusviruslikeparticlespresentingcircumsporozoitejunctionalepitopesthatelicitprotectionagainstmalaria AT johnrmascola designofalphavirusviruslikeparticlespresentingcircumsporozoitejunctionalepitopesthatelicitprotectionagainstmalaria AT peterdkwong designofalphavirusviruslikeparticlespresentingcircumsporozoitejunctionalepitopesthatelicitprotectionagainstmalaria AT robertaseder designofalphavirusviruslikeparticlespresentingcircumsporozoitejunctionalepitopesthatelicitprotectionagainstmalaria |